August 2026 Research Update

This month added clearer signals about what can and cannot be measured reliably in neurodevelopmental epilepsy conditions related to CDKL5. One multi-site study found that certain resting EEG features tracked with how severe a persons symptoms were, while evoked responses to sounds or sights did not show the same link. In a separate qualitative study focused on Lennox-Gastaut syndrome, families and professionals described how some widely used questionnaires feel incomplete or burdensome, especially for nonverbal communication and daily-life challenges. [1] [2]

In 77 people with CDKL5 deficiency disorder, more background slowing on a resting EEG (captured by measures like 1/f slope and power ratios) went along with greater clinical severity on CDKL5-specific severity measures. In the same group, visual and auditory evoked potentials did not show a meaningful relationship to severity. This points to resting EEG background activity as a more promising objective marker of overall disease severity than these particular evoked tests, at least in this dataset. [1]

Separately, focus groups with caregivers, epilepsy advocates, and clinicians discussed tools meant to measure behavior, communication, and quality of life, and they emphasized practical gaps. Participants favored the Aberrant Behavior Checklist for behavior and the Communication Matrix for capturing nonverbal or alternative communication, while some other tools were described as too long or not well matched to developmental levels. They also noted that important areas like sleep, gastrointestinal health, safety, socialization, and caregiver burden are often not captured well. [2]

For families, these studies are mainly about measurement rather than new treatments. The EEG findings suggest that a simple resting brain-wave recording may be one practical way researchers track overall severity in CDD, which could matter later for understanding change over time or for testing therapies, but it is not yet shown to predict an individuals future. The focus-group work highlights why families sometimes feel that study questionnaires do not reflect daily reality, and it clarifies which life areas many people want measured better in future research. What remains uncertain is whether the EEG measures will work the same way across different ages and settings, and whether improved questionnaires will become standard in CDD-focused studies. [1] [2]

This month offered a clearer description of a pattern many caregivers notice: seizures can lessen around febrile (fever) illnesses for some people with CDD. In a nationwide survey in China, over half of respondents reported a meaningful seizure decrease during fever, and a smaller group reported seizure reduction continuing after the fever ended. The study also reported that these fever-related patterns did not line up clearly with differences in clinical features or genetics within the surveyed group, so the reason for the effect is still unknown. [3]

Among 84 survey participants with CDD, 47 (56.0%) had a significant seizure decrease only during febrile episodes, and 20 (23.8%) had seizure reduction that continued after fever. In those with post-fever effects, the reported duration varied from a few days to more than 2 weeks, and the longest reported duration was over 40 days. The survey compared seizure frequency during and after fever with the month before fever, but it did not test a biological explanation for the change. [3]

For patients and caregivers, this survey helps put numbers around a real-world observation: some people with CDD may have fewer seizures during a fever, and some may briefly improve afterward. Because this was a retrospective survey with possible selection and recall bias, it cannot show how often this happens in all families or why it happens, and it should not be treated as a predictable effect. What it does provide is a clearer description of a seizure-change pattern that researchers can now try to study prospectively, including whether body temperature, immune changes, or metabolism could be involved. [3]

A laboratory mouse study this month connected CDKL5 to how early brain circuits process touch, and it linked those circuit changes to later social-behavior differences in the animals. The work focused on the barrel cortex, a brain area mice use to process whisker touch, and found that CDKL5 loss disrupted normal signaling and wiring patterns there. When researchers restored CDKL5 in that specific brain region early in life, the mice showed partial improvement in social behavior, suggesting that timing and brain region may matter for how symptoms develop. [4]

In juvenile male CDKL5 knockout mice, researchers observed problems in whisker-dependent reflexes and in NMDA receptor-dependent signaling (a key pathway for how brain cells communicate and strengthen connections). They also reported changes in the orientation of the receiving branches (dendrites) of certain touch-processing neurons that get input from the thalamus. A neonatal, barrel-cortex-specific CDKL5 rescue partly improved social deficits measured later, supporting the idea that early sensory-circuit development can influence later behaviors in this model. [4]

For families, this is early research in animals, so it does not predict how any specific person with CDD will do or which treatments will work. It does help clarify one possible chain of events: CDKL5 loss may affect how developing brain circuits handle sensory input, and that could contribute to later behavior differences. What remains uncertain is how closely this mouse touch-processing system maps to human sensory processing in CDD and whether similar timing and brain-region effects would be seen in people. For now, the main value is giving researchers a more specific target to study when trying to understand CDD biology. [4]